Bibliographie collaborative AIH – Avril 2016

Allogreffe de cellules souches hématopoïétiques

Proposé par Zoé Van de Wyngaert et Dinh Ngoc Mai, supervisé par Régis Peffault De Latour. 

  • Robinson SP, Boumendil A, Finel H, et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016.
  • Middeke JM, Herbst R, Parmentier S, et al. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016;30(2):261-7.
  • Malard F, Labopin M, Chevallier P, et al. Larger number of invariant natural killer T cells in PBSC allografts is associated with improved GVHD-free, progression-free survival. Blood. 2016.
  • Itonaga H, Iwanaga M, Aoki K, et al. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. Leukemia research. 2016;41:48-55.
  • Forcade E, Kim HT, Cutler C, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
  • El Cheikh J, Sfumato P, Sobh M, et al. Allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning regimen for elderly patients (60 years and older) with hematological malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC). Haematologica. 2016.
  • Berman E, Maloy M, Devlin S, et al. Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation. Leukemia research. 2016;40:33-7.
  • Araki D, Wood BL, Othus M, et al. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol. 2016;34(4):329-36.
  • Arai Y, Kondo T, Yamazaki H, et al. Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. Haematologica. 2016.
  • Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5):646-57


Proposé par Sarah Morin et Jérôme Paillassa, supervisé par Sylvain Thépot. 

  • TROTTIER BJ, SACHS Z, DEFOR TE, et al. Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome. Bone Marrow Transplant 2016 51: 199-204.
  • DAVER N, KANTARJIAN H, RAVANDI F, et al.  A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 2016 30: 268-273.
  • CHESNAIS V, RENNEVILLE A, TOMA A, et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2016 127(6):749-60.
  • LEWINSOHN M, BROWN AL, WEINEL LM, et al. Novel germ line DDX41 mutations define families with a lowerage of MDS/AML onset and lymphoid malignancies. Blood 2016 127(8):1017-23.
  • ZEIDAN AM, SEKERES MA, GARCIA-MANERO G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 2016 30: 649-657.
  • ALHAN C, WESTERS TM, CREMERS EMP, et al. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. Leukemia 2016 30: 658-665.
  • SALLMAN DA, KOMROKI R, VAUPEL C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 2016 30: 666-673.
  • HELSMOORTEL HH, BRESOLIN S, LAMMENS T, et al. LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood 2016 127(9) :1163-72.
  • PATNAIK M and TEFFERI A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J 2016 6: e393; 10.1038.
  • LI W, MORRONE K, KAMBHAMPATI S, et al. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. Leukemia 2016 30(3):536-44.



Proposé par Nicolas Gendron et Clémence Roux, supervisé par David Smadja. 

  • Douxfils J, Haguet H, Mullier F, et al. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. JAMA Oncol. 4 févr 2016;
  • Eikelboom JW, Quinlan DJ, Ryn J van, Weitz JI. Idarucizumab The Antidote for Reversal of Dabigatran. Circulation. 22 déc 2015;132(25):2412‑22.
  • Peyvandi F, Scully M, KremerHovinga JA, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 11 févr 2016;374(6):511‑22.
  • Korenstra J, Wijtvliet EPJ, Veeger NJGM, et al. Effectiveness and safety of dabigatran versus acenocoumarol in « real-world » patients with atrial fibrillation. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 3 févr 2016;
  • Alhenc-Gelas M, Plu-Bureau G, Horellou MH, et al, GEHT genetic thrombophilia group. PROS1 genotype phenotype relationships in a large cohort of adults with suspicion of inherited quantitative protein S deficiency. Thromb Haemost. 29 févr 2016;115(3):570‑9.
  • van der Hulle T, den Exter PL, van den Hoven P, et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured from cancer. Chest. 13 janv 2016;
  • van der Hulle T, den Exter PL, Planquette B, M et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J ThrombHaemost JTH. janv 2016;14(1):105‑13.


Leucémies aiguës

Proposé par Lucille Debus et Ludovic Gabellier, supervisé par Pierre Hirsch. 

  • N Daver, H Kantarjian, F Ravandi and al, A phase study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome,Leukemia (2016) 30, 268-273
  • Barbara L. Asselin, MeenakshiDevidas, Lu Chen, and al, Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404, J Clin Oncol 34:854-862.
  • Han J. M. P. Verhagen,1 Marjon A. Smit,1 Arjo Rutten, and al, Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-transretinoic acid, Blood 2016 127: 458-463
  • Jessica A. Pollard, Michael Loken, Robert B. Gerbing, and al, CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531, J Clin Oncol 34:747-755.
  • C Müller-Tidow1,2,32, P Tschanter1,2,32, C Röllig3, and al, Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia, Leukemia (2016) 30, 555–56
  • Ivey, R.K. Hills, M.A. Simpson, and al, Assessment of Minimal Residual Disease in Standard-Risk AML, N Engl J Med 2016;374:422-33
  • Stéphane Lepretre, Aurore Touzart, Thomas Vermeulin, and al, Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSALL03 Study,J Clin Oncol 34:572-580.
  • Clément Larrue, Estelle Saland, Héléna Boutzen, and al, Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells, Blood. 2016;127(7):882-892)
  • Ajay Vora, Anita Andreano, Ching-Hon Pui, and al, Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy, JClin Oncol 34:919-926.



Proposé par Alexis Talbot et Floriane Theves, supervisé par Laurent Frenzel.

  • Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood [Internet]. 2016 Feb 25 [cited 2016 Apr 9];127(8):971–6.
  •  Nair S, Branagan AR, Liu J, et al. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med. 2016 Feb 11;374(6):555–61.
  • Dimopoulos MA, Cheung MC, Roussel M, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica [Internet]. 2016 Mar 1 [cited 2016 Apr 9];101(3):363–70.
  • Zweegman S, Holt B van der, Mellqvist U-H,  et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood [Internet]. 2016 Mar 3 [cited 2016 Apr 9];127(9):1109–16.
  • Bever KM, Masha LI, Sun F, et al. Riskfactors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica [Internet]. 2016 Jan 1 [cited 2016 Apr 9];101(1):86–90.
  • Jonsdottir G, Lund SH, Bjorkholm M, et al, Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. Haematologica [Internet]. 2016 Apr 1 [cited 2016 Apr 9];101(4):e145–8.
  • Paul G. Richardson, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment ; Blood 02/2016
  •  Valeria Magarottoet et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma ; Blood, 03/2016
  • Pieter Sonneveld et al. Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group ; Blood 03/2016
  • M Moschetta, et al. Targeting vasculogenesis to prevent progression in multiple myeloma ; Leukemia ; 3 February 2016



 Proposé par Florian Chevillon et Claire Bréal, supervisé par Loïc Ysebaert. 

  •  BOISSARD F, LAURENT C, RAMSAY A G et al. Nurse like cells impact on disease progression in chronic lymphocytic leukemia. Blood Cancer J, 2016 Jan; 6(1): e381.
  •  CHANAN-KHAN A, CRAMER P, DEMIRKAN F et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic leukemia (HELIOS) :  a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11.
  •  CHANG JE, HAVIGHURST T, KIM K et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma :  A Wisconsin Oncology Network Study. Br J Haematol.2016 Apr;173(2):283-91.
  •  BUHLER A , WENDTNER CM, KIPPS TJ and al., Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia : data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J.2016 Mar 11;6:e404.
  •  VALSECCHI R, COLTELLA N, BELLONI D and al. HIF-1α régulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood.2016 Apr 21;127(16):1987-97.
  •  FRIEDMAN DR, SIBLEY AB, OWZAR K et al. Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes : A multi-institutional study. Am J Hematol. 2016 Apr 2.
  •  OAKES CC, SEIFERT M, ASSENOV Y et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nature Genetics 2016 March; 48,(3):253–264.
  •  NADEU F, DELGADO Julio, ROYO Cristina, Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia. Blood J. 2016 Apr
  •  ASSOULINE S, BUCCHERI V, DELMER A et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016 Mar;3(3):e128-38.


 Hémopathie bégnine

Proposé par Milena Kohn et Vincent Allain, supervisé par Louis Terriou. 

  • Zhang D, Xu C, Manwani D, et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 18 févr 2016;127(7):801‑9.
  •  Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13;387(10019):661-70.
  •  Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. 18 févr 2016;127(7):839‑48.
  •  Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016 Feb 18;127(7):810-9.
  •  Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 11 févr 2016;374(6):511‑22.
  •  Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016 Apr;3(4):e163-75.
  •  Kuehn HS, Boisson B, Cunningham-Rundles C, et al. Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med. 2016 Mar 17;374(11):1032-43.
  •  Cornet E, Mossafa H, Courel K, et al. Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification. BMC Res Notes. 2016 Mar 2;9(1):138.
  •  Di Pierro E, Brancaleoni V, Granata F. Advances in understanding the pathogenesis of congenital erythropoietic porphyria. Br J Haematol. 2016 Mar 11. [Epubahead of print]
  •  Zhang M, Bracaglia C, Prencipe G, et al. A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. J Immunol. 2016 Mar 15;196(6):2492-503